Clinical Trial Update: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) [Phase 2]

View source ↗

Summary

This document reports the completion and posting of results from the Phase 2 TRAILBLAZER-ALZ trial evaluating LY3002813 in adults with early symptomatic Alzheim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LY3002813

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-02-15